You are viewing the site in preview mode

Skip to main content

Table 3 New biochemical markers in the prognosis assessment of liver cirrhosis

From: Artificial intelligence-based evaluation of prognosis in cirrhosis

Biomarker

First author, references

Study type

Sample source

Detection method

Statistical methods

Target population

Plasma AT-III

Suda et al. [96]

A retrospective study

Blood

Blood test

ROC analysis

Cirrhosis with PVT

Serum CysC and uNAG

Kim et al. [97]

Prospective observational studies

Blood and urine

Blood and urine tests

Multivariate analysis

Patients with AKI in decompensated cirrhosis

Blood ammonia

Tranah et al. [98]

A retrospective study

Blood

Blood test

Random forest model

Complications of cirrhosis

Blood chloride

Sumarsono et al. [99]

Retrospective cohort study

Blood

Blood test

Kaplan–Meier analysis and multivariate Cox proportional risk modeling

Decompensated cirrhosis

t-Cort

Hartl et al. [101]

Prospective observational studies

Blood

Blood test

Multivariate Cox proportional risk model

Advanced CLD

eAlb

Baldassarre et al. [100]

Observational studies

Blood

Blood test

Kaplan–Meier analysis and multivariate Cox proportional risk models

Decompensated cirrhosis

uNGAL

Gambino et al. [102]

Prospective observational studies

Urine

ELISA

Competitive risk proportional risk Model

Patients with acute AKI in decompensated cirrhosis

L-FABP (Urine)

Juanola et al [103]

Prospective cohort study

Blood and Urine

ELISA

Multivariate analysis

Decompensated cirrhosis

PSP

Zanetto et al. [104]

Prospective study cohort study

Blood

ELISA

Multivariate Cox model

Acute decompensated cirrhosis

Metabolite

Zhang et al. [105]

Prospective study cohort study

Blood

Liquid chromatography-ass spectrometry testing

Traditional statistics

machine learning

ACLF

12 proteins

Richards et al. [107]

Cohort study

Blood

High-throughput proteomics

Machine learning

Predicting response to HVPGs in cirrhotic patients with HCV

  1. ROC receiver operating characteristic, AT antithrombin, PVT portal vein thrombosis, CysC serum cystatin C, uNAG urinary N-acetyl-β-D-glucosaminidase, AKI acute kidney injury, t-Cort total cortisol, CLD chronic liver disease, eAlb effective albumin concentration, ELISA enzyme-linked immunosorbent assay, uNGAL urinary neutrophil gelatinase-associated lipocalin, L-FABP liver-type fatty acid binding protein, PSP presepsin, ACLF acute-on-chronic liver failure, HVPG hepatic venous pressure gradient, HCV hepatitis C virus